Freeman Technology relocates to larger premises

Published: 12-Sep-2011
Manufacturing Finance Analysis

New global hq includes manufacturing and office space and an applications laboratory

UK powder characterisation specialist Freeman Technology has relocated to larger premises in Tewkesbury, Gloucestershire after a continued period of growth.

The new 6,000ft2 global headquarters has been equipped to meet the company’s requirements for manufacturing and office space, as well as housing a 300ft2 applications laboratory.

The move into this ultra-modern facility comes just over a decade after the company launched its first powder testing instrument.

Operations director Tim Freeman said: ‘I am delighted to be able to report that demand for the FT4 powder rheometer continues to grow around the world and across powder processing industries.

‘As a result, not only are we building more systems, but we are also continuing to invest in r&d and applications development.

‘This new facility will enable us to scale up our manufacturing and r&d operations and continue to expand well into the future.’

He said the new laboratory would enable the company to carry out additional in-house research into powder behaviour and processing and provide more extensive applications support for customers.

Freeman Technology has enjoyed a continued period of growth and success. This year the company has not only added to its UK-based team but also expanded its global distribution network, with new partnerships covering Japan, India, Singapore, Malaysia, Thailand and Taiwan.

See more

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Read more
Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  4. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
  5. Efficient extraction of proteins from bacterial cells SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Finance

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
Subscribe now